News Image

In the world of growth stocks, NASDAQ:CORT shines as a value proposition.

By Mill Chart

Last update: Nov 10, 2023

Our stock screening tool has pinpointed CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as a growth stock that isn't overvalued. NASDAQ:CORT is excelling in various growth indicators while maintaining a solid financial footing. Furthermore, it remains attractively priced. Let's delve into the specifics below.

Analyzing Growth Metrics

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:CORT has received a 7 out of 10:

  • CORT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.94% yearly.
  • CORT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.18%.
  • CORT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.34% yearly.
  • Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 22.09% on average per year.
  • CORT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.55% yearly.
  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Evaluating Valuation: NASDAQ:CORT

An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NASDAQ:CORT has received a 5 out of 10:

  • Compared to the rest of the industry, the Price/Earnings ratio of CORT indicates a rather cheap valuation: CORT is cheaper than 80.58% of the companies listed in the same industry.
  • CORT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 78.64% of the companies in the same industry.
  • Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than the industry average as 79.13% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, CORT is valued cheaply inside the industry as 86.89% of the companies are valued more expensively.
  • CORT has an outstanding profitability rating, which may justify a higher PE ratio.
  • CORT's earnings are expected to grow with 15.62% in the coming years. This may justify a more expensive valuation.

How We Gauge Health for NASDAQ:CORT

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:CORT has earned a 8 out of 10:

  • CORT has an Altman-Z score of 14.78. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 14.78, CORT belongs to the best of the industry, outperforming 93.20% of the companies in the same industry.
  • There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
  • CORT has a Current Ratio of 3.54. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 3.48 indicates that CORT has no problem at all paying its short term obligations.

Analyzing Profitability Metrics

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:CORT, the assigned 8 is a significant indicator of profitability:

  • CORT has a better Return On Assets (15.38%) than 93.69% of its industry peers.
  • The Return On Equity of CORT (19.79%) is better than 90.78% of its industry peers.
  • With an excellent Return On Invested Capital value of 18.42%, CORT belongs to the best of the industry, outperforming 93.69% of the companies in the same industry.
  • CORT had an Average Return On Invested Capital over the past 3 years of 23.52%. This is significantly above the industry average of 15.36%.
  • The 3 year average ROIC (23.52%) for CORT is well above the current ROIC(18.42%). The reason for the recent decline needs to be investigated.
  • CORT's Profit Margin of 20.31% is amongst the best of the industry. CORT outperforms 93.69% of its industry peers.
  • With an excellent Operating Margin value of 21.80%, CORT belongs to the best of the industry, outperforming 89.81% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 98.65%, CORT belongs to the top of the industry, outperforming 97.57% of the companies in the same industry.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

Check the latest full fundamental report of CORT for a complete fundamental analysis.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/25/2024, 7:00:00 PM)

After market: 22.21 0 (0%)

22.21

-0.27 (-1.2%)

CORT News

News Imagea day ago - Corcept Therapeutics IncorporatedCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
News Imagea day ago - Corcept Therapeutics IncorporatedCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter...

News Image3 days ago - Market News VideoNotable Monday Option Activity: RIOT, SIG, CORT
News Image4 days ago - Corcept Therapeutics IncorporatedCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
News Image7 days ago - ChartmillWhile growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

News Image11 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
News Image11 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image18 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
News Image25 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
News Image25 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Imagea month ago - Market News VideoNotable Monday Option Activity: GME, LULU, CORT
News Image2 months ago - Seeking AlphaCorcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M (NASDAQ:CORT)

Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...

CORT Links
Follow us for more